Vita Life Sciences Limited (AU:VLS)
ASX:VLS
Want to see AU:VLS full AI Analyst Report?
Top Page
Vita Life Sciences Limited
(Sydney:VLS)
Select Model
Select Model
Rating:82Outperform
Price Target:
AU$3.00
▲(19.05% Upside)
Action:Reiterated
Date:02/20/26
The score is driven primarily by strong financial performance (consistent growth, solid margins, and low leverage). Valuation is supportive with a reasonable P/E and a ~4.15% dividend yield. Technicals are positive but moderate, with an established uptrend and largely neutral momentum readings.
Positive Factors
Revenue Growth
Sustained revenue expansion over multiple years shows durable end-market demand and successful distribution execution. A doubling of sales since 2020 indicates scalable product-market fit and provides a base for continued investment in channels and R&D, supporting medium-term growth prospects.
Negative Factors
Margin Compression
A multi-year decline in net margin suggests rising cost pressures or less favourable mix as the business scales. If structural, persistent margin erosion would reduce free cash flow and limit reinvestment or payout capacity unless offset by pricing, efficiency gains, or higher-margin product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue expansion over multiple years shows durable end-market demand and successful distribution execution. A doubling of sales since 2020 indicates scalable product-market fit and provides a base for continued investment in channels and R&D, supporting medium-term growth prospects.
Read all positive factors
Vita Life Sciences Limited (VLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$135.95M
Dividend Yield4.33%
Average Volume (3M)14.76K
Price to Earnings (P/E)13.1
Beta (1Y)-0.03
Revenue Growth17.31%
EPS Growth17.99%
CountryAU
Employees400
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.19
Shares Outstanding54,381,783
10 Day Avg. Volume12,408
30 Day Avg. Volume14,758
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)2.57
Price to Sales (P/S)1.55
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vita Life Sciences Limited Business Overview & Revenue Model
Company Description
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam,...
How the Company Makes Money
Vita Life Sciences Limited generates revenue through the sale of its range of nutritional supplements and health products, which are marketed to both consumers and healthcare professionals. The company employs a multi-channel distribution strategy...
Vita Life Sciences Limited Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 93.27M | 79.50M | 74.16M | 66.89M | 57.10M |
| Gross Profit | 56.03M | 47.24M | 42.60M | 39.74M | 34.81M |
| EBITDA | 15.66M | 13.46M | 13.10M | 11.37M | 11.71M |
| Net Income | 10.44M | 8.78M | 9.08M | 7.08M | 8.29M |
Balance Sheet | |||||
| Total Assets | 82.36M | 71.89M | 59.81M | 51.80M | 45.27M |
| Cash, Cash Equivalents and Short-Term Investments | 35.56M | 28.60M | 24.63M | 15.69M | 15.89M |
| Total Debt | 2.39M | 517.00K | 387.00K | 601.00K | 373.00K |
| Total Liabilities | 26.20M | 19.61M | 16.48M | 15.30M | 14.85M |
| Stockholders Equity | 56.25M | 52.35M | 43.40M | 36.57M | 30.75M |
Cash Flow | |||||
| Free Cash Flow | 15.86M | 5.96M | 12.32M | 7.54M | 5.73M |
| Operating Cash Flow | 16.43M | 6.16M | 12.98M | 7.68M | 5.89M |
| Investing Cash Flow | -570.00K | -198.00K | -660.00K | -139.00K | -155.00K |
| Financing Cash Flow | -9.09M | -2.99M | -2.88M | -3.10M | -4.39M |
Vita Life Sciences Limited Technical Analysis
Positive
2.52
Price Trends
2.50
Positive
2.49
Positive
2.44
Positive
Market Momentum
>-0.01
Positive
51.67
Neutral
35.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VLS, the sentiment is Positive. The current price of 2.52 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.50, and above the 200-day MA of 2.44, indicating a bullish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.67 is Neutral, neither overbought nor oversold. The STOCH value of 35.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VLS.
Vita Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | AU$135.95M | 13.10 | 19.15% | 4.33% | 17.31% | 17.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$63.14M | 2.83 | 10.34% | ― | 15.21% | -141.82% | |
49 Neutral | AU$2.90M | -0.35 | -76.30% | ― | 3.64% | -23.56% | |
47 Neutral | AU$8.56M | -6.68 | 404.65% | ― | 67.74% | 78.79% | |
42 Neutral | AU$19.73M | -5.07 | 4388.00% | ― | -53.90% | 57.52% | |
39 Underperform | AU$6.64M | 0.23 | 93.89% | ― | -29.95% | ― |
* Healthcare Sector Average
AU:VLS
Vita Life Sciences Limited
2.50
0.42
20.13%
AU:EXL
Elixinol Wellness
0.02
<0.01
25.00%
AU:CAN
Cann Group
0.01
>-0.01
-9.09%
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-8.33%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.02
-23.00%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-34.62%
Vita Life Sciences Limited Corporate Events
Vita Life Sciences Cancels 18,584 Shares Under On‑Market Buy-Back
Dec 19, 2025
Vita Life Sciences Limited has cancelled 18,584 ordinary fully paid shares on 19 December 2025 as part of an on-market share buy-back program, according to its latest capital notification. The reduction in issued capital forms part of the company&...
Vita Life Sciences Projects Strong FY2025 Growth Amid Market Expansion
Dec 11, 2025
Vita Life Sciences has issued its FY2025 guidance, projecting significant sales growth to $91m-$92m, up from $79.5m in FY2024, and a pre-tax profit increase to $13.2m-$13.7m. The growth is driven by robust performance in Malaysia and Singapore, wi...
Vita Life Sciences Updates on Share Buy-Back Program
Dec 11, 2025
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported that it bought back 18,584 ordinary fully paid securities on the previous day, adding to a total of 541,740 securities repurchased prior...
Vita Life Sciences Announces Cessation of Securities Through Buy-Back
Dec 10, 2025
Vita Life Sciences Limited announced the cessation of 3,062 ordinary fully paid securities due to an on-market buy-back, effective December 10, 2025. This move could potentially impact the company’s capital structure and market perception, a...
Vita Life Sciences Announces Cessation of Securities
Nov 24, 2025
Vita Life Sciences Limited announced the cessation of 104,392 ordinary fully paid securities as part of an on-market buy-back, effective November 24, 2025. This move is likely to impact the company’s capital structure and could influence its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.